Augmenix Closes $6.1M Series B Financing Round

Augmenix, a Waltham, Mass.-based company focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy, has closed a $6.1m Series B financing round.
The round was led by Ascension Health Ventures (AHV) with participation from existing investors Versant Ventures, Pinnacle Ventures, Catalyst Health Ventures and several private investors.
The proceeds will be used to conduct the clinical and commercial development of its first product SpaceOAR System – an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy – in Europe and the United States, as well as to develop other products in the Augmenix pipeline.

Join the discussion